Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients
Clinical trial NCT06370065 · UNKNOWN
Trial details
- NCT number
- NCT06370065
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-27
- Primary completion
- 2024-06-30
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.